AWP Is Out, “WAMP” Is In, CMS Says; Agency Wants New Rx Pricing Data

The Centers for Medicare & Medicaid Services could develop private-sector sources of drug price information rather than relying on government analyses in determining "widely available market price" for Medicare Part B drugs, a draft proposed rule for reforming the current reimbursement system says